BECTON, DICKINSON AND COMPANY (NYSE:BDX) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April 24, 2018, the Board of Directors of Becton, Dickinson and Company (“BD”) elected Charles Bodner, age 47, to the position of Senior Vice President, Corporate Finance, and Chief Accounting Officer of BD, effective July 1, 2018. In this position, Mr. Bodner will serve as BD’s principal accounting officer, replacing John Gallagher, who has moved to another position within the company. Mr. Bodner had served as BD’s Senior Vice President, Chief Financial Officer, Medical Segment since 2013, and had also served as BD’s Chief Financial Officer, International, since 2017.
Item 5.02 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On April24, 2018, Article IV, Section 1 of the By-Laws of BD concerning board committees was amended to eliminate references to specific committees of the BD board. A copy of BD’s By-Laws, as amended as of April24, 2018, is filed as Exhibit3.1 hereto, the terms of which are incorporated herein by reference.
Exhibits
Exhibit No.Description of Exhibit
hereAbout BECTON, DICKINSON AND COMPANY (NYSE:BDX)
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including diabetes care, medication and procedural solutions, medication management solutions and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The Company’s BD Life Sciences segment consists of various business units, including preanalytical systems, diagnostic systems and biosciences.
